Annals of Indian Academy of Neurology
  Users Online: 2487 Home | About the Journal | InstructionsCurrent Issue | Back IssuesLogin      Print this page Email this page  Small font size Default font size Increase font size
 
CASE REPORT
Ahead of Print

Intrathecal rituximab as a rescue therapy in refractory pure CSF positive, Non-Teratomatous type anti-NMDAR encephalitis


 Department of Neurology, Indo American Hospital Institute of Brain and Spine, Vaikom, Kerala, India

Correspondence Address:
Kurian Thomas,
Consultant Neurologist, Department of Neurology, Indo American Hospital Institute of Brain and Spine, Chemmanakary, Vaikom, Kottayam - 686 143, Kerala
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aian.aian_134_22

NMDAR antibody encephalitis is the most common autoimmune encephalitis characterized by a myriad of neuropsychiatric symptoms. It predominantly affects females and is associated with ovarian teratoma (58%). Nineteen percent do not respond to treatment and are left with serious neurological deficits. A subset of NMDAR encephalitis with antibody positivity in CSF alone without ovarian teratoma is often found to be refractory to treatment. We name them Pure CSF positive, non-teratomatous type anti-NMDAR encephalitis. We report two such cases who responded to intrathecal rituximab, to highlight a novel treatment as a rescue therapy to prevent long-term disability and improve clinical outcomes.


Print this article
 [NEXT]
 [PREV]
 Table of Contents

  Search Pubmed for
 
    -  Krishnan P
    -  Thomas K
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed41    
    PDF Downloaded2    

Recommend this journal